---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-002104"
form_type: "8-K"
ticker: "PLX"
cik: "0001006281"
company_name: "Protalix BioTherapeutics, Inc."
filed_at: "2023-02-27T23:59:59+00:00"
generated_at: "2026-06-18T23:11:07.520575+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Protalix BioTherapeutics enters $20M at-the-market equity offering with H.C. Wainwright

## Summary
- ATM offering of up to $20M of common stock via H.C. Wainwright & Co. as sales agent.
- Proceeds for general corporate purposes, including working capital and clinical trials.
- Shares sold on NYSE American at prevailing market prices in 'at the market' transactions.
- Agreement supplements existing July 2021 ATM facility (amended May 2022).
- Offered under existing shelf registration statement (Form S-3, No. 333-264394).

## SEC filing metadata
- accession: 0001558370-23-002104
- form_type: 8-K
- ticker: PLX
- cik: 0001006281
- company_name: Protalix BioTherapeutics, Inc.
- filed_at: 2023-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006281/000155837023002104/0001558370-23-002104-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006281/000155837023002104/plx-20230227x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-002104
- JSON: https://secwatch.observer/filing/0001558370-23-002104.json
- Plain text: https://secwatch.observer/filing/0001558370-23-002104.txt

## Key facts
- Material Agreements
  Protalix BioTherapeutics, Inc. entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC valued at shares of common stock with aggregate offering price of up to $20,000,000 (effective 2023-02-27).
  - Action: entry
  - Agreement: atm program
  - Counterparty: H.C. Wainwright & Co., LLC
  - Value: shares of common stock with aggregate offering price of up to $20,000,000
  - Effective: 2023-02-27
  source text: On February 27, 2023, Protalix BioTherapeutics, Inc., a Delaware corporation (the "Company") entered into an At The Market Offering Agreement (the "Sales Agreement") with H.C. Wainwright & Co., LLC, as the Company’s sales agent (the "Agent").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1006281/000155837023002104/0001558370-23-002104-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.